LAURUSLABS

Laurus Labs Share Price

 

 

Invest in Laurus Labs with 3.28X leverage

Invest with MTF

Performance

  • Low
  • ₹1,018
  • High
  • ₹1,036
  • 52 Week Low
  • ₹501
  • 52 Week High
  • ₹1,040
  • Open Price₹1,024
  • Previous Close₹1,021
  • Volume664,612

Investment Returns

  • Over 1 Month + 4.57%
  • Over 3 Month + 13.82%
  • Over 6 Month + 53.89%
  • Over 1 Year + 79.58%

Smart Investing Starts Here Start SIP with Laurus Labs for Steady Growth!

Invest Now

Laurus Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 80.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 55,281
  • P/B Ratio
  • Average True Range
  • 25.14
  • EPS
  • 12.67
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 19.23
  • RSI
  • 60.34
  • MFI
  • 55.81

Laurus Labs Financials

Laurus Labs Technicals

EMA & SMA

Current Price
₹1,024.00
+ 2.6 (0.25%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,000.96
  • 50 Day
  • ₹961.77
  • 100 Day
  • ₹901.18
  • 200 Day
  • ₹803.82

Resistance and Support

1011.4 Pivot Speed
  • R3 1,077.90
  • R2 1,052.40
  • R1 1,036.90
  • S1 995.90
  • S2 970.40
  • S3 954.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Laurus Labs Ltd. is a leading pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs), focusing on anti-retrovirals, oncology, and cardiovascular treatments. It also provides contract development and manufacturing (CDMO) services globally.

Laurus Labs has an operating revenue of Rs. 6,358.39 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 9% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 31% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 8% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Laurus Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-23 Quarterly Results & Interim Dividend
2025-07-25 Quarterly Results
2025-04-24 Audited Results & Interim Dividend
2025-01-24 Quarterly Results
2024-10-24 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-10-31 INTERIM Rs.0.80 per share(40%)Interim Dividend
2025-05-09 INTERIM Rs.0.80 per share(40%)Second Interim Dividend
2024-11-06 INTERIM Rs.0.40 per share(20%)Interim Dividend
2024-05-08 INTERIM Rs.0.40 per share(20%)Interim Dividend
2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
View Laurus Labs Dividend History Arrow

Laurus Labs F&O

Laurus Labs Shareholding Pattern

27.59%
8.53%
1.76%
26.17%
0%
23.34%
12.61%

Laurus Labs FAQs

Laurus Labs share price is ₹1,024 As on 10 December, 2025 | 12:44

The Market Cap of Laurus Labs is ₹55281.3 Cr As on 10 December, 2025 | 12:44

The P/E ratio of Laurus Labs is 80.8 As on 10 December, 2025 | 12:44

The PB ratio of Laurus Labs is 12.4 As on 10 December, 2025 | 12:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23